<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509051</url>
  </required_header>
  <id_info>
    <org_study_id>K180302J</org_study_id>
    <nct_id>NCT03509051</nct_id>
  </id_info>
  <brief_title>Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation</brief_title>
  <acronym>MENINGREF</acronym>
  <official_title>Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at risk of various
      bacterial infections, especially due to a progressive decrease of specific antibodies. Around
      90% of HSCT recipients have unprotective titers of specific antibodies to serogroups A and C
      meningogocci .(Parkkali 2001; Mahler 2012).

      Some small studies suggest that the response to meningococcal A and C vaccines is cose to
      100% after 3 doses given 18 months after transplant. Although the response to 2 doses of
      4CMenB is over 75% in other immunocompromised patients (Feavers, 2017), studies with 4CMenB
      are lacking after HSCT. Nevertheless, as serogroup B caused 74% of IMD in Europe between
      2004-2014 (Whittaker, 2017), the meningococcal B vaccination is recommended by the more
      recent guidelines from 6 months after transplant. There are, however, no data on the safety
      and efficacy of this vaccine after hematopoietic stem cell allograft (HSCT).

      The objective of this study is to assess the response to 2 doses of a multicomponent
      meningococcal B vaccine (4CMenB) given at 2 months interval in adult allogeneic HSCT
      recipients transplanted at least 6 months ago. The response will be assessed 1 month and 10
      months after the second dose of vaccine by measuring bactericidal antibodies against NadA,
      fHbp, NHBA and PorAP1 vaccinal antigens according to methods previously reported (Caron
      Lancet Infect Dis 2011). The response rate will be correlated to pre- and post-transplant
      factors. It is hypothesized that 80% of the patients should have protective titers one month
      after the 2nd dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monocentric study. Forty patients are expected. Primary objective: Response rate one month
      after 2 doses of vaccine Secondary objectives: safety, rate of protection before vaccination,
      comparison of the antibody titers at one month vs. at 10 months after the vaccine program.
      Relationship between pre and post-transplant factors.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of patients with Bactericidal titers &gt; 4 to at least one component of the Bexsero vaccine, 1 month after the 2nd dose.</measure>
    <time_frame>1 month</time_frame>
    <description>Vaccine response rate at one month after the 2nd dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of patients with Bactericidal titers &gt; 4 to at least one component of the Bexsero vaccine, 12 months after the 1st dose.</measure>
    <time_frame>12 month</time_frame>
    <description>Vaccine response rate at 12 month after the 1st dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events of vaccination by Bexsero after Allograft of CSH.</measure>
    <time_frame>12 month</time_frame>
    <description>Number of adverse events (non serious and serious) reported during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hematopoietic Stem Cell Transplant</condition>
  <condition>Meningococcal Vaccine</condition>
  <arm_group>
    <arm_group_label>B vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>B vaccination</intervention_name>
    <description>One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.</description>
    <arm_group_label>B vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allogeneic HSCT at least 6 months before

          -  Age ≥ 18 years

          -  Platelet count &gt; 50 G/L

        Exclusion Criteria:

          -  Rituximab administration in the previous 6 months

          -  Relapse of the underlying disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Robin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique des Hopitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Robin, MD</last_name>
    <phone>1 49 81 20 57</phone>
    <phone_ext>33</phone_ext>
    <email>christine.robin@aphp.fr</email>
  </overall_contact>
  <reference>
    <citation>Caron F, du Châtelet IP, Leroy JP, Ruckly C, Blanchard M, Bohic N, Massy N, Morer I, Floret D, Delbos V, Hong E, Révillion M, Berthelot G, Lemée L, Deghmane AE, Bénichou J, Lévy-Bruhl D, Taha MK. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011 Jun;11(6):455-63. doi: 10.1016/S1473-3099(11)70027-5. Epub 2011 Apr 12. Erratum in: Lancet Infect Dis. 2011 Jul;11(7):495.</citation>
    <PMID>21489881</PMID>
  </reference>
  <reference>
    <citation>Mahler MB, Taur Y, Jean R, Kernan NA, Prockop SE, Small TN. Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Jan;18(1):145-9. doi: 10.1016/j.bbmt.2011.07.027. Epub 2011 Aug 4.</citation>
    <PMID>21820392</PMID>
  </reference>
  <reference>
    <citation>Parkkali T, Käyhty H, Lehtonen H, Ruutu T, Volin L, Eskola J, Ruutu P. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. Bone Marrow Transplant. 2001 Jan;27(1):79-84.</citation>
    <PMID>11244441</PMID>
  </reference>
  <reference>
    <citation>Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014 Feb;58(3):309-18. doi: 10.1093/cid/cit816. Erratum in: Clin Infect Dis. 2014 Jul 1;59(1):144.</citation>
    <PMID>24421306</PMID>
  </reference>
  <reference>
    <citation>Whittaker R, Dias JG, Ramliden M, Ködmön C, Economopoulou A, Beer N, Pastore Celentano L; ECDC network members for invasive meningococcal disease. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004-2014. Vaccine. 2017 Apr 11;35(16):2034-2041. doi: 10.1016/j.vaccine.2017.03.007. Epub 2017 Mar 14.</citation>
    <PMID>28314560</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic stem cell transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

